Breaking Down Barriers - A Casual Conversation About INVEST-HD

Описание: Beth Borowsky from Novartis joins HDYO to share more details about INVEST-HD, a clinical trial investigating the safety and tolerability of votoplam and to determine whether votoplam slows disease progression in patients with early symptomatic Huntington's disease (HD).

To find out more about INVEST-HD at clinicaltrials.gov.

Breaking Down Barriers is sponsored by uniQure, Novartis, Ferrer, Prilenia, Wave Life Sciences, Teva Pharmaceuticals, Neurocrine, Skyhawk Therapeutics, Alnylam, Roche and the Griffin Foundation.